Volume | 26,082 |
|
|||||
News | - | ||||||
Day High | 6.91 | Low High |
|||||
Day Low | 6.65 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Pulse Biosciences Inc | PLSE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.71 | 6.65 | 6.91 | 6.69 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
248 | 26,082 | $ 6.78 | $ 176,749 | - | 3.78 - 13.62 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:15:51 | 14 | $ 6.85 | USD |
Pulse Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
376.14M | 54.99M | - | 0 | -42.21M | -0.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Pulse Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PLSE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 7.26 | 7.59 | 6.595 | 6.92 | 128,274 | -0.40 | -5.51% |
1 Month | 7.696 | 8.34 | 6.595 | 7.51 | 188,945 | -0.836 | -10.86% |
3 Months | 8.95 | 11.6398 | 6.595 | 8.70 | 165,686 | -2.09 | -23.35% |
6 Months | 4.01 | 13.62 | 3.78 | 9.02 | 231,853 | 2.85 | 71.07% |
1 Year | 5.87 | 13.62 | 3.78 | 7.85 | 198,581 | 0.99 | 16.87% |
3 Years | 21.02 | 29.16 | 1.18 | 7.25 | 153,651 | -14.16 | -67.36% |
5 Years | 16.47 | 45.82 | 1.18 | 9.76 | 128,119 | -9.61 | -58.35% |
Pulse Biosciences Description
Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfunctional cells while preserving surrounding non-cellular tissue, a combination that may potentially lead to both improved efficacy and less collateral tissue damage. Substantial revenue is generated from North America Majorly due to the sale of systems. |